Incidence of Metastasis in the Central Nervous System in Advanced Breast Cancer Treated With CDK 4/6 Inhibitors: A Multicenter, Retrospective Study

Abstract

Central nervous system (CNS) metastasis remains a major cause of mortality in advanced breast cancer (ABC). While cyclin-dependent kinase 4/6 inhibitors (CDKIs) combined with endocrine therapy (ET) delay resistance in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative ABC, their impact on CNS metastasis development has not been fully elucidated. This retrospective study analyzed 435 ABC patients without baseline CNS metastases who received first-line ET with or without CDKIs across three Chinese hospitals (August 2018–July 2022). Primary end points included CNS as the first metastatic site, CNS metastasis-free survival (CNSM-FS), and CNS metastasis incidence over time. Secondary end points were progression-free survival (PFS) and overall survival (OS). The results indicated that the addition of CDKIs to ET significantly reduced the incidence of CNS as the first site of metastasis (3.7% vs. 9.5% with ET alone; p = 0.0015) and extended CNSM-FS (71.6 months vs. 63.6 months, respectively; hazard ratio [HR], 0.53; 95% CI, 0.31–0.92). Overall, CNS metastasis incidence was lower with ET + CDKIs (7.9% vs. 15.5%, p = 0.014), and improvements were observed in both PFS and OS. These findings suggest that ET + CDKIs as first-line therapy in ABC may reduce CNS metastasis risk and extend CNSM-FS, offering a potential strategy for preventing CNS metastases.

Keywords

advanced breast cancer / CDK 4/6 inhibitor / CNS metastasis / endocrine therapy

References

[1] N. Howlader, S. F. Altekruse, C. I. Li, et al., “US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status,” Journal of the National Cancer Institute 106, no. 5 (2014): dju055.

[2] F. Cardoso, S. Paluch-Shimon, E. Senkus, et al., “5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5),” Annals of Oncology 31, no. 12 (2020): 1623-1649.

[3] W. J. Gradishar, M. S. Moran, J. Abraham, et al., “Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network 20, no. 6 (2022): 691-722.

[4] M. Cristofanilli, N. C. Turner, I. Bondarenko, et al., “Fulvestrant Plus Palbociclib Versus Fulvestrant Plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial,” Lancet Oncology 17, no. 4 (2016): 425-439.

[5] R. S. Finn, M. Martin, H. S. Rugo, et al., “Palbociclib and Letrozole in Advanced Breast Cancer,” New England Journal of Medicine 375, no. 20 (2016): 1925-1936.

[6] M. P. Goetz, M. Toi, M. Campone, et al., “MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer,” Journal of Clinical Oncology 35, no. 32 (2017): 3638-3646.

[7] G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, et al., “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer,” New England Journal of Medicine 375, no. 18 (2016): 1738-1748.

[8] H. Kennecke, R. Yerushalmi, R. Woods, et al., “Metastatic Behavior of Breast Cancer Subtypes,” Journal of Clinical Oncology 28, no. 20 (2010): 3271-3277.

[9] N. Lin, J. Bellon, and E. Winer, “CNS Metastases in Breast Cancer,” Journal of Clinical Oncology 22, no. 17 (2004): 3608-3617.

[10] M. Gounder and D. Spriggs, “Inclusion of Patients With Brain Metastases in Phase I Trials: An Unmet Need,” Clinical Cancer Research 17, no. 12 (2011): 3855-3857.

[11] R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg, “Breast Cancer Metastasis to the Central Nervous System,” American Journal of Pathology 167, no. 4 (2005): 913-920.

[12] A. Darlix, G. Louvel, J. Fraisse, et al., “Impact of Breast Cancer Molecular Subtypes on the Incidence, Kinetics and Prognosis of Central Nervous System Metastases in a Large Multicentre Real-Life Cohort,” British Journal of Cancer 121, no. 12 (2019): 991-1000.

[13] H. Gauthier, M. Guilhaume, F. Bidard, et al., “Survival of Breast Cancer Patients With Meningeal Carcinomatosis,” Annals of Oncology 21, no. 11 (2010): 2183-2187.

[14] G. Griguolo, S. Pouderoux, M. V. Dieci, et al., “Clinicopathological and Treatment-Associated Prognostic Factors in Patients With Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology,” Oncologist 23, no. 11 (2018): 1289-1299.

[15] M. Kuksis, Y. Gao, W. Tran, et al., “The Incidence of Brain Metastases Among Patients With Metastatic Breast Cancer: A Systematic Review and Meta-Analysis,” Neuro-Oncology 23, no. 6 (2021): 894-904.

[16] P. W. Sperduto, N. Kased, D. Roberge, et al., “Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases,” International Journal of Radiation and Oncology in Biology and Physics 82, no. 5 (2012): 2111-2117.

[17] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[18] B. Geoerger, F. Bourdeaut, S. G. DuBois, et al., “A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients With Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors,” Clinical Cancer Research 23, no. 10 (2017): 2433-2441.

[19] A. Patnaik, L. S. Rosen, S. M. Tolaney, et al., “Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients With Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors,” Cancer Discovery 6, no. 7 (2016): 740-753.

[20] T. J. Raub, G. N. Wishart, P. Kulanthaivel, et al., “Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination With Temozolomide in an Intracranial Glioblastoma Xenograft,” Drug Metabolism and Disposition 43, no. 9 (2015): 1360-1371.

[21] A. Tien, J. Li, X. Bao, et al., “A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort,” Clinical Cancer Research 25, no. 19 (2019): 5777-5786.

[22] C. Anders, E. L. Rhun, T. D. Bachelot, et al., “A Phase II Study of abemaciclib in Patients (pts) With Brain Metastases (BM) Secondary to HR+, HER2− Metastatic Breast Cancer (MBC),” Journal of Clinical Oncology 37, no. supplement S15 (2019): 1017-1017.

[23] S. M. Tolaney, S. Sahebjam, E. Le Rhun, et al., “A Phase II Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer,” Clinical Cancer Research 26, no. 20 (2020): 5310-5319.

[24] M. D. DeWire, C. Fuller, O. Campagne, et al., “A Phase I and Surgical Study of Ribociclib and Everolimus in Children With Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study,” Clinical Cancer Research 27, no. 9 (2021): 2442-2451.

[25] M. Kubeczko, M. Jarząb, A. Krzywon, D. Gräupner, A. Polakiewicz-Gilowska, and D. Gabryś, “Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients With Brain Metastases,” Journal of Clinical Medicine 12, no. 5 (2023).

[26] E. Hamilton and J. Infante, “Targeting CDK4/6 in Patients With Cancer,” Cancer Treatment Reviews 45 (2016): 129-138.

[27] Comprehensive Molecular Portraits of Human Breast Tumours. Nature 490, no. 7418 (2012): 61-70.

[28] D. Zardavas, J. Baselga, and M. Piccart, “Emerging Targeted Agents in Metastatic Breast Cancer,” Nature Reviews Clinical Oncology 10, no. 4 (2013): 191-210.

[29] P. K. Brastianos, S. L. Carter, S. Santagata, et al., “Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets,” Cancer Discovery 5, no. 11 (2015): 1164-1177.

[30] D. J. H. Shih, N. Nayyar, I. Bihun, et al., “Genomic Characterization of Human Brain Metastases Identifies Drivers of Metastatic Lung Adenocarcinoma,” Nature Genetics 52, no. 4 (2020): 371-377.

[31] G. Shapiro, “Cyclin-Dependent Kinase Pathways as Targets for Cancer Treatment,” Journal of Clinical Oncology 24, no. 11 (2006): 1770-1783.

[32] J. J. Gao, J. Cheng, E. Bloomquist, et al., “CDK4/6 Inhibitor Treatment for Patients With Hormone Receptor-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer: A US Food and Drug Administration Pooled Analysis,” Lancet Oncology 21, no. 2 (2020): 250-260.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.